GSK Thailand
GSK Thailand is the Thai subsidiary of GSK PLC (UK-parent global pharmaceutical group). Thailand operation is among the largest MNC originator subsidiaries by Thai market share (~8% by value). Therapeutic focus: respiratory (Seretide, Trelegy, Relvar), vaccines (Shingrix, Arexvy RSV, vaccines portfolio), HIV (ViiV Healthcare partnership), and oncology (Jemperli, other specialty therapies). Not listed in Thailand; financial performance consolidated into GSK PLC parent. Competitively positioned via strong respiratory, vaccines franchise benefiting from Thailand's ageing, NCD demand growth.
Snapshot
Headline numbers a buyer checks first.
Thai market share
~8% by value
FY2024
Parent
GSK PLC (UK)
Subsidiary since 1958
Focus areas
Respiratory, vaccines, HIV, oncology
FY2024
Status
Private Thai subsidiary
Ongoing
What this subsidiary actually does
GSK Thailand imports, markets, and distributes GSK PLC-originated pharmaceutical products in Thailand through MoPH central procurement, hospital direct supply, and retail-pharmacy channels. Respiratory franchise (Seretide, Trelegy, Relvar) is a pillar of GSK Thailand revenue, aligned with rising asthma, COPD prevalence. Vaccine portfolio (Shingrix shingles, Arexvy RSV, Hepatitis, Rotavirus, Cervarix HPV, Infanrix paediatric, adolescent) is material to public-health procurement. ViiV Healthcare HIV franchise (Tivicay, Juluca, Cabenuva) serves MoPH, UCS HIV programs alongside GPO-manufactured generic ARVs.[]
Strategic position: GSK is a top-tier MNC originator subsidiary in Thailand with strong respiratory, vaccines franchise. Competitive dynamics: rivals Pfizer, Novartis, Roche, Sanofi, AstraZeneca in specialty; patent-expiry, biosimilar transition compress originator pricing over time. UCS, NLEM procurement wins via specialty, novel-products that generics don't yet cover. Parent-group global strategic focus, product pipeline, patent-expiry schedule determine subsidiary trajectory.[, ]
Therapeutic portfolio
Respiratory
Seretide, Trelegy, Relvar — COPD and asthma
Respiratory franchise generates the largest Thai revenue contribution. Seretide (fluticasone/salmeterol) remains a top-selling ICS-LABA; Trelegy (triple therapy) targets severe COPD. Thailand's rising NCD burden — asthma prevalence ~12%, COPD ~7% of adults — underpins structural demand.
Vaccines
Shingrix, Arexvy, Cervarix, Rotarix
GSK vaccine portfolio spans Shingrix (shingles), Arexvy (RSV adult), Cervarix (HPV), Rotarix (rotavirus), Infanrix (paediatric), and meningococcal series. MoPH national immunisation programme and UCS procurement drive volume at regulated pricing; private-market premium pricing applies for newer vaccines.
HIV
ViiV Healthcare — Tivicay, Juluca, Cabenuva
ViiV Healthcare (GSK majority-owned) supplies integrase-inhibitor ARVs (Tivicay/dolutegravir, Juluca dual therapy, Cabenuva injectable) to Thailand's MoPH HIV programme. GPO-manufactured generic ARVs dominate NLEM volume, but novel ViiV regimens serve treatment-failure and simplification cases.
Oncology
Zejula, Jemperli — specialty pipeline
GSK specialty oncology — Zejula (niraparib, ovarian cancer), Jemperli (dostarlimab, endometrial cancer) — is a smaller-revenue but strategically growing segment as MoPH cancer treatment guidelines expand access to targeted therapies. Relevant to private-hospital oncology budgets and MoPH specialty procurement.
MNC originator pharmaceutical peer comparison — Thailand
Estimated Thai market share by value and therapeutic focus, FY2024
Parent
Novartis (Switzerland)
Est. Thai market share
~6%
Therapeutic focus
Ophthalmology, oncology, immunology
AstraZeneca Thailand
Parent
AstraZeneca (UK-Sweden)
Est. Thai market share
Therapeutic focus
Oncology, cardiovascular, respiratory
Sanofi Thailand
Parent
Sanofi (France)
Est. Thai market share
~5%
Therapeutic focus
Vaccines, diabetes, rare disease
| Entity | Parent | Est. Thai market share | Therapeutic focus |
|---|---|---|---|
| Pfizer Thailand | Pfizer (US) | ~10% | Vaccines, oncology, hospital generics |
| GSK Thailand | GSK PLC (UK) | ~8% | Respiratory, vaccines, HIV, oncology |
| Novartis Thailand | Novartis (Switzerland) | ~6% | Ophthalmology, oncology, immunology |
| AstraZeneca Thailand | AstraZeneca (UK-Sweden) | ~8% | Oncology, cardiovascular, respiratory |
| Sanofi Thailand | Sanofi (France) | ~5% | Vaccines, diabetes, rare disease |
Key drivers 2025-2026
NCD demand
Respiratory NCD prevalence rising
Thailand's ageing population and urban air-quality deterioration (PM2.5 in Chiang Mai, Bangkok) sustain structural asthma and COPD demand. GSK respiratory franchise positioned to benefit from diagnostic expansion and treatment intensification under MoPH NCD management protocols.
Vaccines
RSV and shingles adult vaccine uptake
Arexvy (RSV adult) and Shingrix (shingles) face a large under-vaccinated Thai 60-plus population of 12-13 million. Private-sector vaccination drive via hospitals and pharmacy chains is the primary adoption channel; private-pay pricing vs subsidised-programme entry is the key scenario variable.
Patent cliff
Seretide generic pressure and NLEM review
Seretide faces incremental generic-ICS-LABA competition as patents expire. NLEM review cycles can shift government procurement from branded to generic formularies. Watch NLEM 2025-2026 update for respiratory category revisions.
Watchpoints
Respiratory franchise vs generics
Seretide, Trelegy, Relvar competitive position.
Vaccine pipeline, MoPH procurement
Shingrix, Arexvy, paediatric vaccine wins.
ViiV HIV franchise, GPO ARV competition
Novel HIV therapies vs GPO-manufactured generics.
Patent-expiry, biosimilar pressure
Rolling patent-expiry transition, biosimilar NLEM inclusion.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Pfizer Thailand
MNC originator peer; different therapeutic-area strength.
Open Market profile →
Competitor
Government Pharmaceutical Organisation (GPO)
State ARV manufacturer competing in HIV segment.
Open Market profile →
Sector peer
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
Open Market profile →
Sector peer
Mega Lifesciences
Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~ $463.8M.
Open Market profile →
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
GlaxoSmithKline Thailand — Subsidiary Disclosures
National List of Essential Medicines (NLEM) — Committee, Pricing
Publisher
Ministry of Public Health, Drug Subcommittee
Grade
Primary
As of
2025-12-31
| Source | Publisher | Grade | As of |
|---|---|---|---|
| GlaxoSmithKline Thailand — Subsidiary Disclosures | GSK Thailand (MNC subsidiary) | Well established | 2025-12-31 |
| National List of Essential Medicines (NLEM) — Committee, Pricing | Ministry of Public Health, Drug Subcommittee | Primary | 2025-12-31 |
Reports featuring this profile
Thailand Pharmaceuticals Market Intelligence
UK-parent MNC originator subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market share by value.
Open report →
Sits alongside 7 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
GSK Thailand branded innovator MNC.
Open report →
Sits alongside 7 other Atlas profiles